CLARITEV CORP CLASS A (CTEV)
Health Care · healthcare technology / payment integrity services · NYSE
Claritev leverages decades of claims data and AI-driven analytics to provide payment integrity, network management, and cost-transparency solutions that reduce healthcare spending for payers and employers.
What CLARITEV CORP CLASS A does
Claritev Corporation is a healthcare technology, data, and analytics company that provides solutions to improve transparency, affordability, and payment accuracy within the U.S. healthcare system. The company operates a platform that connects payers, employers, and providers to manage medical costs, reduce waste, and streamline claims processing. Its services include out-of-network cost management, provider network access, payment and revenue integrity, and data-driven insights.
Recent developments
The company raised its full-year 2026 revenue guidance to a range of $1 billion to $1.02 billion, citing strength in the TPA market. It also reported strong bookings of over $70 million for the first half of 2026 and announced the formal closure of a DOJ antitrust grand jury investigation.
From CLARITEV CORP CLASS A's filing of 2026-08-07.
Themes: healthcare cost containment, payment integrity, AI in healthcare, healthcare transparency, claims processing, health plan administration
Fundamentals
- Price$24.33 as of 2026-10-08 close
- Market cap$412M as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return-57.6% 2025-10-08 close $57.36 → 2026-10-08 close $24.33
- P/En/a negative earnings
- Net margin-29.4% FY2025, SEC XBRL
- Debt / equity311.26 as of 2026-09-03
- Revenue growth (YoY)+5.5% as of 2026-09-03
- Revenue CAGR (3y)-3.7% SEC XBRL
- Beta1.29 as of 2026-09-03
- Last reported earnings2026-08-07 SEC EDGAR Form 8-K (Item 2.02)
How CTEV compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CLARITEV CORP CLASS A looks technically
CLARITEV CORP CLASS A (CTEV) is trading 10.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 31 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 7 trading days ago. It is 67.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 10.9% below its 200-day average, the long-term trend line — a long-term downtrend | -10.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $31.75 | $31.75 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $27.30 | $27.30 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 33.9205. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 31 trading days ago — a "golden cross", a bullish long-term signal | 31 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control | 26.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) | 37.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($20.24 to $33.31) — its "stochastic" reading is 31 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 31.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $73.68 | $73.68 |
|---|---|---|
| From the 52-week high | it is 67.0% below its 52-week high (its highest price of the past year) | -67.0% |
| Above the 52-week low | it is 111.0% above its 52-week low (its lowest price of the past year) | +111.0% |
| Below the 52-week high | it is 67.0% below its highest point of the past year | 67.0% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day low about 7 trading days ago | 7 sessions |
| All-time high | its highest closing price on record is $517.20 (set on 2020-07-13) | $517.20 |
| Given back of the 52-week move | over the past year its closes ranged ($13.47 to $71.36), and it has recovered roughly a quarter of its fall from last year’s high — 19% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $49.25 to $51.10. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 18.8% |
| From the all-time high | it is 95.3% below its all-time high | -95.3% |
| Nearest price level | it is trading 6.1% below a resistance level at $25.82 — a price it turned at twice since 2025-05-27, most recently on 2026-07-14. Since 2024-10-08 it has 3 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +6.1% |
| All-time low | its lowest closing price on record is $4.80 (set on 2024-11-19) | $4.80 |
| Above the all-time low | it is 406.9% above its all-time low | +406.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 78% of it) | 78th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.19 between its high and its low — about 9.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.19 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $16.95 and $37.57 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $16.95 – $27.26 – $37.57 |
| Typical daily range (% of price) | its price moves about 9.0% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.0% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges below its 200-day average price (10.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.39× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.8% |
|---|---|---|
| Open gap | it gapped 3.1% above the previous close 4 sessions ago and has not traded back through the level it left behind at 21.31 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.1% |
| Gap filled | a 2.4% gap down opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 36.5 percentage points (the stock lost 35.5% while the market gained 1.0%) | -36.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 27.8 percentage points (the stock lost 24.0% while the market gained 3.8%) | -27.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 25.2 percentage points (the stock gained 42.6% while the market gained 17.5%) | +25.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 72.6 percentage points (the stock lost 57.6% while the market gained 15.0%) | -72.6% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a strong downtrend, with sellers in control, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 24% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 12.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -23.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is sitting right on the average price paid so far this year, so the typical buyer over that stretch is roughly break-even. That average is $24.42 — a volume-weighted average of daily closes over 183 sessions, not a true tick-by-tick VWAP. | -0.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 23% below the average price paid since it last reported on 2026-08-07 (its 10-Q), so the typical buyer over that stretch is under water. That average is $31.50 — a volume-weighted average of daily closes over 44 sessions, not a true tick-by-tick VWAP. | -22.8% |
Price levels it has turned at before
CTEV last closed at $24.33 on 2026-10-08. Since 2024-10-08 it has turned at 3 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $25.82 | Resistance | 6.1% above the last close | turned there twice · 2025-05-27 to 2026-07-14 |
| $27.97 | Resistance | 15.0% above the last close | turned there twice · 2026-01-12 to 2026-06-22 |
| $19.61 | Support | 19.4% below the last close | turned there twice · 2025-03-21 to 2026-02-12 |
| $18.99 | Support | 21.9% below the last close | turned there four times · 2024-12-27 to 2026-03-16 |
| $33.77 | Resistance | 38.8% above the last close | turned there twice · 2026-06-12 to 2026-08-20 |
| $11.48 | Support | 52.8% below the last close | turned there twice · 2025-01-08 to 2026-05-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $33.92.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $25.38 and $31.12 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $20.24.
This reading has stood for 1 trading day, since 2026-10-08.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · beating the market · Most volatile (6%+ typical daily range) · Trading at this year’s average price paid (anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.80 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$46.00 range $30.00 – $73.00; median $43.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CTEV
- Consensus EPS estimate$1.71 next reporting period, as of 2026-10-08
- Estimate change, 30 days$0.00 (0.0%) from $1.71, on 2026-09-03, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Increasing litigation from healthcare providers and members regarding cost management and reimbursement practices.","Dependency on retaining key payer clients and the success of their plan member outcomes.","Ongoing regulatory and antitrust scrutiny from government entities, including civil investigative demands."]
What changed in the latest 10-Q
AI-assisted comparison of CTEV's 10-Q filed 2026-08-07 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer MD&A (filed 2026-08-07) adds reference to 'Part II, Item 1A of this Form 10-Q' as an additional location where risk factors are discussed in the forward-looking statements paragraph.
- Newer MD&A (filed 2026-08-07) results of operations table includes data for 'Three Months Ended June 30, 2026 and 2025' and 'Six Months Ended June 30, 2026 and 2025' with figures including Revenues of $257,478 and $241,570, Costs of services of $67,667 and $60,823, General and administrative expenses of $55,389 and $51,118, Depreciation of $24,796 and $25,261, Amortization of intangible assets of $85,908 and $85,971, Loss on disposal of leases of $252 and $1,689, Loss on disposal of assets of $57 and $130, and Total expenses of $234,069 and $224,992.
- Removed:
- Older MD&A (filed 2026-05-07) results of operations table contains data for 'Three months ended March 31, 2026 and 2025' with figures including Revenues of $244,678 and $231,330, Costs of services of $69,080 and $60,436, General and administrative expenses of $57,830 and $46,968, Depreciation of $25,183 and $24,546, Amortization of intangible assets of $85,908 and $85,971, Loss on disposal of leases of $38 and $3,317, Loss on sale of assets of $— and $350, Total expenses of $238,039 and $221,588, Operating income of $6,639 and $9,742, Interest expense of $99,542 and $91,636, Interest income of $(182) and $(488), Transaction costs related to refinancing transaction of $— and $7,792, Loss on extinguishment of debt of $— and $670, and Net loss before taxes of $(92,721) and $(89,868).
- Reworded:
- Company Overview description changed from 'a technology, data and insights company focused on improving transparency, affordability and quality' (older, filed 2026-05-07) to 'a healthcare technology, data and insights company focused on delivering affordability, transparency and quality' (newer, filed 2026-08-07).
- Forward-looking statements paragraph wording changed 'under the heading "Risk Factors"' (older, filed 2026-05-07) to 'in each case under the heading "Risk Factors"' (newer, filed 2026-08-07).
- Forward-looking statements paragraph changed 'other factors' (older, filed 2026-05-07) to 'othe r factors' with a space inserted between 'othe' and 'r' (newer, filed 2026-08-07).
- Forward-looking statements paragraph changed 'our other filings with the Securities and Exchange Commission' (older, filed 2026-05-07) to 'our other filings with the SEC' (newer, filed 2026-08-07).
- Results of operations table line item name changed from 'Loss on sale of assets' (older, filed 2026-05-07) to 'Loss on disposal of assets' (newer, filed 2026-08-07).
- Results of operations table dropped 'Operating income', 'Interest expense', 'Interest income', 'Transaction costs related to refinancing transaction', 'Loss on extinguishment of debt', and 'Net loss before taxes' rows that appeared in the older table (filed 2026-05-07).
- Notes:
- The older filing (filed 2026-05-07) covers the three months ended March 31, 2026, while the newer filing (filed 2026-08-07) covers the three and six months ended June 30, 2026; therefore, the results of operations tables contain different reporting periods and are not directly comparable line-by-line.
- The newer filing text appears to end abruptly after 'Total expenses' in the results of operations table, so it may be truncated in the source provided.
Risk Factors
- Added:
- Newer filing adds a detailed litigation risk factor titled 'We operate in a litigious environment which may adversely affect our financial results.'
- Newer filing adds disclosure that the Company may be and has been involved in legal actions and claims including employment matters, breach of contract, violations of laws and regulations and other commercial matters, and governmental investigations.
- Newer filing adds disclosure that healthcare providers have become more resistant to cost management techniques and are engaging in litigation, including suits challenging insurers' claims adjudication and reimbursement decisions.
- Newer filing adds disclosure of legal theories under which litigation may be brought, including breach of contract, misrepresentation, unjust enrichment, antitrust, ERISA, and RICO violations.
- Newer filing adds disclosure that litigation is increasingly brought involving multiple parties, multiple claims, or on a class-wide basis.
- Newer filing adds references to 'Claims and Litigation' in Note 7, Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements.
- Newer filing adds disclosure regarding an August 2024 confidential grand jury subpoena from the DOJ Antitrust Division in connection with a health insurance investigation.
- Newer filing adds disclosure that on June 17, 2026, the DOJ informed the Company that the antitrust grand jury proceeding was being brought to a close and the Company was not under any criminal investigation, and that on July 6, 2026, the Company received official confirmation that the proceeding was closed.
- Newer filing adds disclosure that on May 19, 2026, the Company received a civil investigative demand from the DOJ, and that the Company continues to cooperate fully with the DOJ.
- Newer filing adds disclosure that the Company does not know when the DOJ investigation will be completed, the entirety of facts that will be discovered, or what actions the government may take.
- Newer filing adds disclosure that a negative outcome could cause significant fines, penalties, reputational harm, loss of client confidence and business, and other harm.
- Newer filing adds disclosure that new federal and state laws and regulations or changes adversely impacting healthcare providers or insurers could lead to increased litigation risk.
- Newer filing adds disclosure that many healthcare providers and insurers have greater financial resources and may be more willing to engage in litigation.
- Newer filing adds disclosure that certain agreements include indemnification provisions that may subject the Company to costs and damages.
- Newer filing adds disclosure that insurance coverage may not apply or may be insufficient to cover all losses or types of claims.
- Newer filing adds disclosure that litigation could be costly and time-consuming and divert management attention.
- Newer filing adds disclosure that lawsuits could materially and adversely affect results, especially if they proliferate, and may affect clients' use of the Company's products and solutions, especially cost management products and solutions.
- Removed:
- Older filing states there were no material changes during the three months ended March 31, 2026 to the risk factors previously disclosed in the 2025 Annual Report on Form 10-K.
- Reworded:
- The introductory sentence changed from stating no material changes during the three months ended March 31, 2026 (older filing) to stating no material changes during the three months ended June 30, 2026 other than as set forth below (newer filing).
- The older filing includes the Item 5. Other Information section and Item 6. Exhibits and signature pages, while the newer filing includes Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities and Item 5. Other Information sections. These sections are not part of Risk Factors but appear in the provided source text.
- Notes:
- The newer filing source text is truncated at the end of the Risk Factors section and appears to include subsequent report sections, which may affect the completeness of the comparison.
- The older filing source text includes sections beyond Risk Factors (Item 5, Item 6, Signature), while the newer filing includes Item 2 and the beginning of Item 5.
- The comparison is based solely on the provided text excerpts and cannot be independently verified against the full filings.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 4 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 2 sells ($276075) — 1 selling insider
- Last 90 days · read to 2026-10-042 buys ($249664) · 4 sells ($919345) — 1 buying, 3 selling insiders
- Last 180 days · read to 2026-10-047 buys ($743108) · 4 sells ($919345) — 4 buying, 3 selling insiders
Cluster buying: 4 different insiders reported open-market purchases (SEC code P) of CTEV within a 30-day window between 2026-05-18 and 2026-06-09. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-21. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CTEV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CTEV as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 986,536
- Reported value $33,650,742
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CTEV's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CTEV had 941,196 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CTEV had 5.55% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.55 days to cover at the same settlement.
- Reported short interest (shares) 941,196
- Short interest (% of shares outstanding) 5.55%
- Prior settlement (shares) 918,699
- Reported change 2.45%
- Days to cover (reported) 8.55
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Change Healthcare (UNH)
- Cotiviti
- Evolent Health (EVH)
- Healthcare Bluebook
- MultiPlan (MPLN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CTEV vs…
CLARITEV CORP CLASS A is found in…
Frequently asked questions
What does CLARITEV CORP CLASS A (CTEV) do?
Claritev Corporation is a healthcare technology, data, and analytics company that provides solutions to improve transparency, affordability, and payment accuracy within the U.S. healthcare system. The company operates a platform that connects payers, employers, and providers to manage medical costs, reduce waste, and streamline claims processing. Its services include out-of-network cost management, provider network access, payment and revenue integrity, and data-driven insights.
What sector is CLARITEV CORP CLASS A (CTEV) in?
CLARITEV CORP CLASS A (CTEV) is classified in the Health Care sector. Its industry is healthcare technology / payment integrity services. It trades on NYSE.
Who are CLARITEV CORP CLASS A's (CTEV) competitors?
Notable peers of CLARITEV CORP CLASS A (CTEV) include Change Healthcare, Cotiviti, Evolent Health, Healthcare Bluebook and MultiPlan. This peer set is informational only — not financial advice.
Is CLARITEV CORP CLASS A (CTEV) overbought or oversold right now?
CLARITEV CORP CLASS A (CTEV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CTEV come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.